Asthma deaths; persistent and preventable mortality

Histopathology

Volumn 43, Issue 2, 2003, Pages 105-117

  Sidebotham, H J ^a   Roche, William R ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Airway remodelling; Bronchial asthma; Drug therapy; Mortality statistics; Necropsy

Indexed keywords

ANTIASTHMATIC AGENT;

ANAPHYLAXIS; ASTHMA; AUTOPSY; BASEMENT MEMBRANE; CELL INFILTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; EMPHYSEMA; EOSINOPHIL; EPITHELIUM; HISTOLOGY; HUMAN; HYPERPLASIA; LUNG EMBOLISM; MEDIASTINUM; MORTALITY; MUSCLE HYPERTROPHY; PATHOGENESIS; PERIODIC MEDICAL EXAMINATION; PNEUMOTHORAX; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; REVIEW; SMOOTH MUSCLE; SOCIAL PSYCHOLOGY; VASCULARIZATION;

ASTHMA; CAUSE OF DEATH; ENGLAND; HUMANS; PRIMARY PREVENTION; SURVIVAL RATE; WALES;

GOES;

EID: 0042160026     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2003.01664.x     Document Type: Review

References (117)

1. Kuehni CE, Davis A, Brooke AM, Silverman M. Are all wheezing disorders in very young (preschool) children increasing in prevalence? Lancet 2001: 357; 1821-1825.
2. Saxena S, Eliahoo J, Majeed A. Socioeconomic and ethnic group differences in self reported health status and use of health services by children and young people in England: cross sectional study. Br. Med. J. 2002: 325; 520.
3. Woolcock AJ, Bastiampillai SA, Marks GB, Keena VA. The burden of asthma in Australia. Med. J. Austral. 2001: 175; 141-145.
4. Goodwin RD, Pine DS. Respiratory disease and panic attacks among adults in the United States. Chest 2002: 122; 645-650.
5. Von Behren J, Kreutzer R, Hernandez A. Self-reported asthma prevalence in adults in California. J. Asthma 2002: 39; 429-440.
6. Reid DWEC, Hendrick VJ, Aitken TC, Berrill WT, Stenton SC, Hendrick DJ. Age-dependent inaccuracy of asthma death certification in Northern England. 1991-1992. Eur. Respir. J. 1998: 12; 1079-1083.
7. Drazen JM, Turino GM. Progress at the interface of inflammation and asthma. Report of an ATS-sponsored workshop November, 1993. Am. J. Respir. Crit. Care Med. 1995: 152; 386-387.
8. Mormile F, Chiappini F, Feola G, Ciappi G. Deaths from asthma in Italy (1974-1988): is there a relationship with changing pharmacological approaches? J. Clin. Epidemiol. 1996: 49; 1459-1466.
9. Registrar General, Mortality statistics, cause. Review of the Registrar General on deaths by cause, sex and age, in England and Wales, 2000, Series DH2, 2000: 7; 40-197.
10. Dow L, Fowler L, Phelps L et al. Prevalence of untreated asthma in a population sample of 6000 older adults in Bristol, UK. Thorax 2001: 56; 472-476.
11. Campbell MJ, Holgate ST, Johnston SL. Trends in asthma mortality. Br. Med. J. 1997: 315; 1012.
12. Campbell MJ, Cogman GR, Holgate ST, Johnston SL. Age specific trends in asthma mortality in England and Wales 1983-95: results of an observational study. Br. Med. J. 1997: 314; 1439-1441.
13. Sears MR, Rea HH, de Boer G et al. Accuracy of certification of deaths due to asthma. A national study. Am. J. Epidemiol. 1986: 124; 1004-1011.
14. Jackson R., Sears MR, Beaglehole R, Rea HH. International trends in asthma mortality: 1970 to 1985. Chest 1988: 94; 914-919.
15. Woolcock AJ. Worldwide differences in asthma prevalence and mortality. Why is asthma mortality so low in the USA? Chest 1986: 90; S40-S45.
16. Berrill WT. Is the death rate from asthma exaggerated? Evidence from West Cumbria. Br. Med. J. 1993: 306; 193-194.
17. Whallett EJ, Ayres JG. Labelling shift from acute bronchitis may be contributing to the recent rise in asthma mortality in the 5-34 age group. Respir. Med. 1993: 87; 183-186.
18. Wright SC, Evans AE, Sinnamon DG, MacMahon J. Asthma mortality and death certification in Northern Ireland. Thorax 1994: 49; 141-143.
19. Ormerod LP, Stableforth DE. Asthma mortality in Birmingham 1975-7: 53 deaths. Br. Med. J. 1980: 280; 687-690.
20. A Subcommittee of the British Thoracic Research Committee. Accuracy of death certificates in bronchial-asthma. Thorax 1984: 39; 505-509.
21. Guite HF, Burney PGJ. Accuracy of recording of deaths from asthma in the UK: the false negative rate. Thorax 1996: 51; 924-928.
22. Hunt LW, Silverstein MD, Reed CE. O'Connell EJ. O'Fallon WM, Yunginger JW. Accuracy of the death certificate in a population-based study of asthmatic patients. JAMA 1993: 269; 1947-1952.
23. Smyth ET, Wright SC, Evans AE, Sinnamon DG, MacMahon J. Death from airways obstruction: accuracy of certification in Northern Ireland. Thorax 1996: 51; 293-297.
24. Bronchial asthma and the environment [Editorial]. Lancet 1986: 2; 786-787.
25. Fuller RW. The asthma death problem revisited. Br. J. Clin. Pharmacol. 1996: 42; 11-14.
26. Crane J, Flatt A, Jackson R et al. Prescribed fenoterol and death from asthma in New Zealand. 1981-83: case-control study. Lancet 1989: 1; 917-922.
27. Pearce N, Grainger J, Atkinson M et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand. 1977-81. Thorax 1990: 45; 170-175.
28. Grainger J, Woodman K, Pearce N et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 1991: 46; 105-111.
29. O'Donnell TV, Rea HH, Holst PE, Sears MR. Fenoterol and fatal asthma. Lancet 1989: 1; 1070-1071.
30. Buist AS, Burney PGJ. Feinstein AR et al. Fenoterol and fatal asthma. Lancet 1989: 1; 1071.
31. Spitzer WO, Buist AS. Case-control study of prescribed fenoterol and death from asthma in New Zealand. 1977-81. Thorax 1990: 45; 645.
32. 2-agonists. Am. J. Epidemiol. 1996: 144; 1161-1169.
33. Beasley R, Burgess C, Pearce N, Woodman K, Crane J. Confounding by severity does not explain the association between fenoterol and asthma death. Clin. Exp. Allergy 1994: 24; 660-668.
34. 2-agonists. Am. J. Epidemiol. 1997: 146; 885-886.
35. Spitzer WO, Suissa S, Ernst P et al. The use of β-agonists and the risk of death and near death from asthma. N. Engl. J. Med. 1992: 326; 501-506.
36. Suissa S, Ernst P, Boivin JF et al. A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. Am. J. Respir. Crit. Care Med. 1994: 149; 604-610.
37. Bremner P, Burgess C, Beasley R et al. Nebulized fenoterol causes greater cardiovascular and hypokalemic effects than equivalent bronchodilator doses of salbutamol in asthmatics. Resp. Med. 1992: 86; 419-423.
38. Pearce N, Beasley R, Crane J, Burgess C, Jackson R. End of the New Zealand asthma mortality epidemic. Lancet 1995: 345; 41-44.
39. Keating G, Mitchell EA, Jackson R, Beaglehole R, Rea H. Trends in sales of drugs for asthma in New Zealand, Australia, and the United Kingdom. 1975-81. Br. Med. J. 1984: 289; 348-351.
40. British Thoracic Society. Guidelines for management of asthma in adults: I - chronic persistent asthma. Br. Med. J. 1990: 301; 651-653.
41. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the management of asthma. Thorax 2003: 58 (suppl. I); i1-i92.
42. Abramson MJ, Bailey MJ, Couper FJ et al. Are asthma medications and management related to deaths from asthma? Am. J. Respir. Crit. Care Med. 2001: 163; 12-18.
43. Majeed A, Ferguson J, Field J. Prescribing of beta-2 agonists and inhaled steroids in England: trends between 1992 and 1998, and association with material deprivation, chronic illness and asthma mortality rates. J. Pub. Health Med. 1999: 21; 395-400.
44. Crane J, Pearce N, Burgess C, Woodman K, Robson B, Beasley R. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int. J. Epidemiol. 1992: 21; 737-744.
45. Ulrik CS, Frederiksen J. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. Chest 1995: 108; 10-15.
46. Suissa S, Blais L, Ernst P. Patterns of increasing β-agonist use and the risk of fatal or near-fatal asthma. Eur. Respir. J. 1994: 7; 1602-1609.
47. Grant EN, Lyttle CS, Weiss KB. The relation of socioeconomic factors and racial/ethnic differences in US asthma mortality. Am. J. Public Health 2000: 90; 1923-1925.
48. Lang DM, Polansky M. Patterns of asthma mortality in Philadelphia from 1969 to 1991. N. Engl. J. Med. 1994: 331; 1542-1546.
49. Jones AP, Bentham G. Health service accessibility and deaths from asthma in 401 local authority districts in England and Wales, 1988-92. Thorax 1997: 52; 218-222.
50. Weitzman JB, Kanarek NF, Smialek JE. Medical examiner asthma death autopsies. A distinct subgroup of asthma deaths with implications for public health preventive strategies. Arch. Pathol. Lab. Med. 1998: 122; 691-699.
51. Burr ML, Davies BH, Hoare A et al. A. confidential inquiry into asthma deaths in Wales. Thorax. 1999: 54; 985-989.
52. Guite HF, Dundas R, Burney PGJ. Risk factors for death from asthma, chronic obstructive pulmonary disease. and cardiovascular disease after a hospital admission for asthma. Thorax 1999: 54; 301-307.
53. Turner-Warwick M. Epidemiology of nocturnal asthma. Am. J. Med. 1988: 85; S6-8.
54. Joseph KS, Blais L, Ernst P, Suissa S. Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers. Br. Med. J. 1996: 312; 79-82.
55. Kolbe J, Fergusson W, Vamos M, Garrett J. Case-control study of severe life threatening asthma (SLTA) in adults: psychological factors. Thorax 2002: 57; 317-322.
56. Jones K, Berrill WT, Bromly CL, Hendrick DJ. A confidential enquiry into certified asthma deaths in the North of England, 1994-96: influence of co-morbidity and diagnostic inaccuracy. Respir. Med. 1999: 93; 923-927.
57. Anto JM, Sunyer J, Rodriguez-Roisin R, Suarez-Cervera M, Vazquez L. Community outbreaks of asthma associated with inhalation of soybean dust. Toxieoepidemiological Committee. N. Engl. J. Med. 1989: 320; 1097-1102.
58. O'Hollaren MT, Yunginger JW, Offord KP et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N. Eng. J. Med. 1991: 324; 359-363.
59. Anderson HR, de Leon AP, Bland JM, Bower JS, Emberlin J, Strachan DP. Air pollution, pollens, and daily admissions for asthma in London 1987-92. Thorax 1998: 53; 842-848.
60. Williams TJ, Tuxen DV, Scheinkestel CD, Czarny D, Bowes G. Risk-factors for morbidity in mechanically ventilated patients with acute severe asthma. Am. Rev. Respir. Dis. 1992: 146; 607-615.
61. Curschmann H. Über bronchiolitis exsudativa und ihr Verhaltnis zum Asthma nervosum. Dtsch. Arch. Klin. Med. 1883: 32; 1-34.
62. Walsh JJ, Dietlein LF, Low FN, Burch GE, Mogabgab WJ. Bronchotracheal response in human influenza. Arch. Int. Med. 1961: 108; 376-388.
63. Dunnill MS. The pathology of asthma, with special reference to changes in the bronchial mucosa. J. Clin. Pathol. 1960: 13; 27-33.
64. Saetta M, Di Stefano A, Rosina C, Thiene G, Fabbri LM. Quantitative structural-analysis of peripheral airways and arteries in sudden fatal asthma. Am. Rev. Respir. Dis. 1991: 143; 138-143.
65. Shimura S, Andoh Y, Haraguchi M, Shirato K. Continuity of airway goblet cells and intraluminal mucus in the airways of patients with bronchial asthma. Eur. Resp. J. 1996: 9; 1395-1401.
66. Messer JW, Peters GA, Bennett WA. Causes of death and pathologic findings in 304 cases of bronchial asthma. Chest 1960: 38; 616-624.
67. Sur S, Crotty TB, Kephart GM et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am. Rev. Respir. Dis. 1993: 148; 713-719.
68. Reid LM. The presence or absence of bronchial mucus in fatal asthma. J. Allergy Clin. Immunol. 1987: 80; 415-416.
69. Strunk RC. Death due to asthma. New insights into sudden unexpected deaths, but the locus remains on prevention. Am. Rev. Respir. Dis. 1993: 148: 550-552.
70. Carroll N, Elliot J, Morton A, James A. The structure of large and small airways in nonfatal and fatal asthma. Am. Rev. Respir. Dis. 1993: 147; 405-410.
71. Ordonez CL, Khashayar R, Wong HH et al. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am. J. Respir. Crit. Care Med. 2001: 163; 517-523.
72. Aikawa T, Shimura S, Sasaki H, Ebina M, Takishima T. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest 1992: 101; 916-921.
73. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. Am. J. Respir. Crit. Care Med. 1997: 156; 229-233.
74. Gleich GJ, Flavahan NA, Fujisawa T, Vanhoutte PM. The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. J. Allergy Clin. Immunol. 1988: 81; 776-781.
75. Chung KF, Rogers DF, Barnes PJ, Evans TW. The role of increased airway microvascular permeability and plasma exudation in asthma. Eur. Respir. J. 1990: 3; 329-337.
76. Groneberg DA, Eynott PR. Lim S et al. Expression of respiratory mucins in fatal status asthmaticus and mild asthma. Histopathology 2002: 40; 367-373.
77. Cluroe A, Holloway L, Thomson K, Purdie G, Beasley R. Bronchial gland duct ectasia in fatal bronchial asthma: association with interstitial emphysema. J. Clin. Pathol. 1989: 42; 1026-1031.
78. Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela T. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am. Rev. Respir. Dis. 1985: 131; 599-606.
79. Beasley R., Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am. Rev. Respir. Dis. 1989: 139; 806-817.
80. Montefort S, Roberts JA, Beasley R., Holgate ST, Roche WR. The site of disruption of the bronchial epithelium in asthmatic and non-asthmatic subjects. Thorax 1992: 47; 499-503.
81. Vanhoutte PM. Epithelium-derived relaxing factor(s) and bronchial reactivity. Am. Rev. Respir. Dis. 1988: 138; S24-S30.
82. Del Donno M, Bittesnich D, Chetta A, Olivieri D, Lopez-Vidriero MT. The effect of inflammation on mucociliary clearance in asthma - an overview. Chest 2000: 118; 1142-1149.
83. Ordonez C, Ferrando R, Hyde DM, Wong HH, Fahy JV. Epithelial desquamation in asthma. Am. J. Respir. Crit. Care Med. 2000: 162; 2324-2329.
84. Soderberg M, Hellstrom S, Sandstrom T, Lundgren R, Bergh A. Structural characterization of bronchial mucosal biopsies from healthy volunteers: a light and electron microscopical study. Eur. Respir. J. 1990: 3; 261-266.
85. Naylor B. The shedding of the mucosa of the bronchial tree in asthma. Thorax 1962: 17; 69-72.
86. Roche WR, Montefort S, Baker J, Holgate ST. Cell adhesion molecules and the bronchial epithelium. Am. Rev. Respir Dis. 1993: 148; S79-S82.
87. Johnston SL, Pattemore PK, Sanderson G et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am. J. Respir. Crit. Care Med. 1996: 154; 654-660.
88. Bardin PG, Johnston SL, Pattemore PK. Viruses as precipitants of asthma symptoms II. Physiology and mechanisms. Clin. Exp. Allergy 1992: 22; 809-822.
89. + T lymphocytes contribute to the pathology of asthma death. Am. J. Respir. Crit. Care Med. 2001: 164; 560-564.
90. Ward C, Pais M, Bish R et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002: 57; 309-316.
91. Amin K, Ludviksdottir D, Janson C et al. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. Am. J. Respir. Crit. Care Med. 2000: 162; 2295-2301.
92. Faul JL, Tormey VJ, Leonard C et al. Lung immunopathology in cases of sudden asthma death. Eur. Respir. J. 1997: 10; 301-307.
93. Djukanovic R, Lai CKW, Wilson JW et al. Bronchial mucosal manifestations of atopy: a comparison of markers of inflammation between atopic asthmatics, atopic nonasthmatics and healthy controls. Eur. Resp. J. 1992: 5; 538-544.
94. Kepley CL, McFeeley PJ, Oliver JM, Lipscomb MF. Immunohistochemical detection of human basophils in postmortem cases of fatal asthma. Am. J. Resp. Crit. Care Med. 2001: 164; 1053-1058.
95. Awadh N, Muller NL, Park CS, Abboud RT, FitzGerald JM. Airway wall thickness in patients with near fatal asthma and control groups: assessment with high resolution computed tomographic scanning. Thorax 1998: 53; 248-253.
96. Kuwano K, Bosken CH, Pare PD, Bai TR, Wiggs BR, Hogg JC. Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am. Rev. Resp. Dis. 1993: 148; 1220-1225.
97. Kasahara K, Shiba K, Ozawa T, Okuda K, Adachi M. Correlation between the bronchial subepithelial layer and whole airway wall thickness in patients with asthma. Thorax 2002: 57; 242-246.
98. Roche WR, Beasley R, Williams JH, Holgate ST. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989: 1; 520-524.
99. Wiggs BR, Bosken C, Pare PD, James A, Hogg JC. A model of airway narrowing in asthma and in chronic obstructive pulmonary disease. Am. Rev. Resp. Dis. 1992: 145; 1251-1258.
100. Heard BE, Hossain S, Hyperplasia of bronchial muscle in asthma. J. Pathol. 1973: 110; 319-331.
101. Ebina M, Takahashi T, Chiba T, Motomiya M. Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D morphometric study. Am. Rev. Resp. Dis. 1993: 148; 720-726.
102. Bai TR, Prasad FW. Abnormalities in airway smooth muscle in fatal asthma. Am. Rev. Resp. Dis. 1990: 141; 552-557.
103. Bai TR. Abnormalities in airway smooth-muscle in fatal asthma. A comparison between trachea and bronchus. Am. Rev. Resp. Dis. 1991: 143; 441-443.
104. Laitinen A, Laitinen LA. Vascular beds in the airways of normal subjects and asthmatics. Eur. Resp. J. 1990: 3; S658-S662.
105. Djukanovic R, Roche WR, Wilson JW et al. Mucosal inflammation in asthma. Am. Rev. Resp. Dis. 1990: 142; 434-457.
106. de la Grandmaison GL, Paraire F, Postmortem revelation of sickle cell disease following fatal episode of acute bronchial asthma. Forensic Sci. Int. 2002: 126; 48-52.
107. Pumphrey RSH, Roberts ISD. Postmortem findings after fatal anaphylactic reactions. J. Clin. Pathol. 2000: 53; 273-276.
108. Yunginger JW, Nelson DR, Squillace DL et al. Laboratory investigation of deaths due to anaphylaxis. J. Forensic Sci. 1991: 36; 857-865.
109. Salkie ML, Mitchell I, Revers CWB et al. Postmortem serum levels of tryptase and total and specific IgE in fatal asthma. Allergy Asthma Proc. 1998: 19; 131-133.
110. Randall B, Butts J, Halsey JF. Elevated postmortem tryptase in the absence of anaphylaxis. J. Forensic Sci. 1995: 40; 208-211.
111. Edston E, van Hage-Hamsten M. Beta-tryptase measurements post-mortem in anaphylactic deaths and in controls. Forensic Sci. Int. 1998: 93; 135-142.
112. Blainey D, Lomas D, Beale A, Partridge M. The cost of acute asthma - how much is preventable? Health Trends 1990/91: 22; 151-153.
113. Griffiths C, Naish J, Sturdy P, Pereira F. Prescribing and hospital admissions for asthma in east London. Br. Med. J. 1996: 312; 481-482.
114. Parameswaran K, Hildreth AJ, Chadha D, Keaney NP, Taylor IK, Bansal SK. Asthma in the elderly: underperceived, underdiagnosed and undertreated: a community survey. Resp. Med. 1998: 92; 573-577.
115. Enright PL, McClelland RL, Newman AB, Gottlieb DJ, Lebowitz MD. Underdiagnosis and undertreatment of asthma in the elderly. Chest 1999: 116; 603-613.
116. Sin DD, Tu JV. Underuse of inhaled steroid therapy in elderly patients with asthma. Chest 2001: 119; 720-725.
117. Roche WR. Inflammatory and structural changes in the small airways in bronchial asthma. Am. J. Resp. Crit. Care Med. 1998: 157; S191-S194.